It looks like you have an older browser that is not supported by this site. Please click here to update.
It looks like you have an older browser that is not supported by this site. Please click here to update.
Posted Jan 6, 20223 min Read
These medications are authorized only for those with mild to moderate illness in individuals with confirmed COVID-19 who are at high risk for progression, are not hospitalized, and are within five days of symptom onset. They are NOT for pre-exposure or post-exposure prophylaxis. These treatments are in very limited supply and require a prescription. A prescription does not guarantee the medication will be available.
The facility should screen whether the resident is eligible for the antivirals and discuss with the clinical provider and/or pharmacy to ensure there is no contraindication for the medication. Please see the below links for fact sheets for each of these medications’ dosing, cautions, contraindications, and prescribing information.
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID (fda.gov)
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR (fda.gov)
If a resident is deemed eligible, the facility should contact their LTC pharmacy or contact Probari directly at 317-804-4102 and provide the following information:
Probari will be available 8 a.m. – 5 p.m. Mondays through Fridays, and 10 a.m. – 2 p.m. Saturdays.
If necessary, Probari will reach out to multiple locations to secure the medication. If a treatment course is available, Probari will give the resident’s and prescriber’s information to the dispensing hospital or pharmacy and ask them to hold the medication under the resident’s name. Probari will call the facility or LTC pharmacy back with either an availability update or dispensing details.
The facility (the clinical provider or other staff) will have to call the hospital or pharmacy to send a prescription for the resident to receive the medication and to arrange pick up.
Given the limited supply and extremely high demand, please be aware that courses might not be available for many who meet the treatment criteria.